Precision Medicine Podcast · Trapelo

How AI is Revolutionizing Precision Medicine: Dr. Douglas Flora & Dr. Sanjay Juneja on the Future of Cancer Care

·50 min·1 clip
The episode opens with Karen Cushman framing Season 6 around the practical problems oncologists, reference labs, and payers are dealing with as precision medicine grows. She introduces Dr. Douglas Flora as a returning guest with deep experience in oncology services, AI education, and related publishing and consulting work. The OncDoc joins as the other half of the conversation. The goal is straightforward: help listeners keep up with a field that is changing fast. Karen asks the question many listeners are probably asking. Are we still waiting for the AI era in cancer care, or are we already in it? Both guests say the era is already here, while also stressing that the technology is still early. One comparison makes that point clear: AI tools are still like five-year-olds learning to stumble around before they become full-fledged players. From there the conversation narrows to multi-cancer early detection. The guests describe current blood tests as useful, but not yet great. Sensitivity and specificity still need work. They talk through a familiar medical approach for improving screening: start with pre-test likelihood and focus on people whose risk makes testing more likely to pay off. They then connect that logic to AI. Instead of testing everyone the same way, future systems could identify target-rich environments and make the next generation of MCED tools smarter. That matters because better targeting could improve accuracy and lower cost at the same time. The difference could be a move from tests that cost thousands of dollars to tools that sit closer to hundreds, which would widen access beyond the wealthier patients already paying for them. The episode closes on a practical note: AI is not some distant abstraction here, but a set of decisions about screening, equity, and how cancer care should improve.

As heard by us

A clear look at AI in oncology that stays grounded in clinical tradeoffs.

AI and precision medicine sit inside the present of cancer care here, not some distant promise. The discussion keeps its footing on practical questions: what multi-cancer early detection can and cannot do, why current blood tests still run into sensitivity and specificity…

Read the full review in PlayNext →

Why you'd press play

You want a clear map of how AI is being discussed in oncology and where the limits still are.

Read the full recommendation in PlayNext →
Listen to the show on